Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The booming market for weight-loss drugs has been somewhat restrained due to lingering supply issues. Against that backdrop, Novo Holdings, Novo Nordisk’s controlling shareholder, said in ...

For the first time since May, Novo Nordisk is gradually increasing the supply of its highly sought-after weight loss drug ...

The timeline for when supply will fully meet demand remains unclear. Novo Nordisk maintains a strong position in the ... These tools provide a clearer picture of investment opportunities, enabling ...

In its fourth-quarter results statement, Novo Nordisk said that it had started to increase the supply of starting doses for Wegovy in the US since the start of the year thanks to those investments ...

In my previous Novo Nordisk article, I indicated the growth deceleration challenges encountered by the Danish biopharma company. It also needed to manage the supply chain snag that has persisted ...